SAR441344治疗系统性红斑狼疮的疗效和安全性 (APATURA)
SAR441344 治疗系统性红斑狼疮的疗效和安全性:一项随机、双盲、安慰剂对照、2 期概念验证研究
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include:
- Study duration: 36 weeks
- Treatment duration: 24 weeks
- Visit frequency: every 2 weeks
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Kyiv、乌克兰、02091
- Investigational Site Number : 8040006
-
Kyiv、乌克兰、02125
- Investigational Site Number : 8040001
-
Poltava、乌克兰、36011
- Investigational Site Number : 8040005
-
-
-
-
-
Tbilisi、乔治亚州、0102
- Investigational Site Number : 2680005
-
Tbilisi、乔治亚州、0114
- Investigational Site Number : 2680004
-
Tbilisi、乔治亚州、0131
- Investigational Site Number : 2680001
-
Tbilisi、乔治亚州、0159
- Investigational Site Number : 2680003
-
Tbilisi、乔治亚州、0186
- Investigational Site Number : 2680002
-
-
-
-
-
Moscow、俄罗斯、111539
- Investigational Site Number : 6430002
-
-
-
-
-
Gyula、匈牙利、5700
- Investigational Site Number : 3480002
-
Székesfehérvár、匈牙利、8000
- Investigational Site Number : 3480003
-
-
-
-
-
Ankara、土耳其(türkiye)、06800
- Investigational Site Number : 7920003
-
Denizli、土耳其(türkiye)、20070
- Investigational Site Number : 7920002
-
Sakarya、土耳其(türkiye)、54100
- Investigational Site Number : 7920004
-
-
-
-
-
Chihuahua City、墨西哥、31000
- Investigational Site Number : 4840006
-
Chihuahua City、墨西哥、31210
- Investigational Site Number : 4840011
-
Mexico City、墨西哥、11850
- Investigational Site Number : 4840007
-
Veracruz、墨西哥、91900
- Investigational Site Number : 4840008
-
-
Mexico City
-
Mexico City、Mexico City、墨西哥、03100
- Investigational Site Number : 4840009
-
Mexico City、Mexico City、墨西哥、06700
- Investigational Site Number : 4840004
-
-
Nuevo León
-
Monterrey、Nuevo León、墨西哥、64460
- Investigational Site Number : 4840001
-
-
Yucatán
-
Mérida、Yucatán、墨西哥、97070
- Investigational Site Number : 4840005
-
-
-
-
-
São Paulo、巴西、04265-000
- Centro Paulista de Investigaçăo Clínica - CEPIC- Site Number : 0760004
-
São Paulo、巴西、04014-002
- IBCC - Núcleo de Pesquisa e Ensino- Site Number : 0760007
-
-
Paraná
-
Curitiba、Paraná、巴西、80030-110
- Centro de Estudos em Terapias Inovadoras- Site Number : 0760002
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、巴西、90480-000
- LMK Servicos Medicos- Site Number : 0760001
-
-
São Paulo
-
São José do Rio Preto、São Paulo、巴西、15090-000
- Fundação Faculdade Regional de Medicina de São José do Rio Preto- Site Number : 0760006
-
-
-
-
-
Athens、希腊、124 62
- Investigational Site Number : 3000001
-
Athens、希腊、115 27
- Investigational Site Number : 3000004
-
Heraklion、希腊、711 10
- Investigational Site Number : 3000003
-
Larissa、希腊、415 00
- Investigational Site Number : 3000005
-
Thessaloniki、希腊、546 36
- Investigational Site Number : 3000002
-
-
-
-
Milano
-
Milan、Milano、意大利、20132
- IRCCS Ospedale San Raffaele-Site Number : 3800001
-
-
Roma
-
Rome、Roma、意大利、00168
- Fondazione Policlinico Universitario Agostino Gemelli-Site Number : 3800002
-
-
-
-
Los Lagos Region
-
Osorno、Los Lagos Region、智利、5311092
- Investigational Site Number : 1520002
-
-
Maule Region
-
Talca、Maule Region、智利、3465584
- Investigational Site Number : 1520003
-
-
Reg Metropolitana de Santiago
-
Santiago、Reg Metropolitana de Santiago、智利、7640881
- Investigational Site Number : 1520001
-
Santiago、Reg Metropolitana de Santiago、智利、7510047
- Investigational Site Number : 1520004
-
-
-
-
-
Vacoas、毛里求斯、72218
- Investigational Site Number : 4800001
-
-
-
-
-
San Juan、波多黎各、00917
- GCM Medical Group - San Juan - Calle Jose Marti- Site Number : 8400011
-
-
-
-
-
Sankt Gallen、瑞士、9007
- Investigational Site Number : 7560001
-
-
-
-
Alabama
-
Vestavia Hills、Alabama、美国、35216
- Accel Research Sites Network - Birmingham- Site Number : 8400003
-
-
Arizona
-
Chandler、Arizona、美国、85225
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler- Site Number : 8400026
-
Mesa、Arizona、美国、85210
- Arizona Arthritis & Rheumatology Associates - South Vineyard Avenue- Site Number : 8400022
-
Sun City、Arizona、美国、85351
- Arizona Arthritis & Rheumatology Research - Sun City- Site Number : 8400027
-
Tucson、Arizona、美国、85748
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson Southeast- Site Number : 8400023
-
-
California
-
Santa Monica、California、美国、90404
- Saint John's Physician Partners- Site Number : 8400015
-
Simi Valley、California、美国、93065
- Millennium Clinical Trials - Simi Valley- Site Number : 8400004
-
-
Florida
-
DeBary、Florida、美国、32713
- Omega Research Consultants - Debary - North Charles Richard Beall Boulevard- Site Number : 8400002
-
Margate、Florida、美国、33063
- Vitalia Medical Research - Margate- Site Number : 8400039
-
Miramar、Florida、美国、33027
- Innovia Research Center- Site Number : 8400037
-
Plantation、Florida、美国、33324
- Integral Rheumatology and Immunology Specialists- Site Number : 8400014
-
Sanford、Florida、美国、32771
- Infigo Clinical Research- Site Number : 8400016
-
-
New Mexico
-
Santa Fe、New Mexico、美国、87505
- Inspire Santa Fe Medical Group- Site Number : 8400019
-
-
New York
-
New York、New York、美国、10032
- Columbia University Irving Medical Center- Site Number : 8400009
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73116
- RAO - Rheumatology Associates of Oklahoma- Site Number : 8400013
-
-
Tennessee
-
Memphis、Tennessee、美国、38119
- Private Practice - Dr. Ramesh C. Gupta I- Site Number : 8400008
-
-
Texas
-
Austin、Texas、美国、78745
- Tekton Research - West Gate- Site Number : 8400001
-
Colleyville、Texas、美国、76034
- Precision Comprehensive Clinical Research Solutions - Colleyville- Site Number : 8400017
-
Fort Worth、Texas、美国、76109
- Lone Start Arthritis & Rheumatology Associates- Site Number : 8400025
-
Houston、Texas、美国、77054
- Prolato Clinical Research Center- Site Number : 8400005
-
Irving、Texas、美国、75039
- AARA Clinical Research - Lone Star Arthritis & Rheumatology Associates - Irving- Site Number : 8400024
-
Lubbock、Texas、美国、79410
- West Texas Clinical Research- Site Number : 8400018
-
-
-
-
-
Madrid、西班牙、28046
- Investigational Site Number : 7240001
-
Valencia、西班牙、46014
- Investigational Site Number : 7240005
-
Valladolid、西班牙、47012
- Investigational Site Number : 7240004
-
-
Barcelona [Barcelona]
-
Sabadell、Barcelona [Barcelona]、西班牙、08208
- Investigational Site Number : 7240002
-
-
-
-
-
Buenos Aires、阿根廷、1121
- Investigational Site Number : 0320004
-
Buenos Aires、阿根廷、1023
- Investigational Site Number : 0320006
-
Buenos Aires、阿根廷、1111
- Investigational Site Number : 0320001
-
Buenos Aires、阿根廷、1430
- Investigational Site Number : 0320002
-
-
Buenos Aires
-
Berazategui、Buenos Aires、阿根廷、1886
- Investigational Site Number : 0320008
-
-
Tucumán Province
-
San Miguel de Tucumán、Tucumán Province、阿根廷、4000
- Investigational Site Number : 0320003
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Diagnosis of SLE for at least 6 months prior to screening by fulfilling the Revised Criteria for Classification of SLE according to the 1997 Update of the 1982 ACR criteria
- Positive antinuclear antibody (ANA) (titer ≥1:80) during screening
- Positivity for at least one serological characteristic
- Total hSELENA-SLEDAI score ≥6 (including points attributed from arthritis and rash) during screening and at least 4 points from clinical features at randomization as confirmed by a Sponsor-selected independent reviewer(s)
- At least 1 BILAG A score or 2 BILAG B scores during screening as confirmed by a Sponsor-selected independent reviewer(s)
- Receiving at least one of the standard of care (SOC) for SLE (combination is possible)
- Body weight within 45 kg to 120 kg (inclusive) at screening
- Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion Criteria:
- Primary diagnosis of a rheumatic disease besides SLE or an inflammatory joint or skin disease other than SLE that could confound the disease activity assessments
- Active and severe lupus nephritis
- Active severe or unstable neuropsychiatric SLE including but not limited to seizures, psychosis, acute confusional state, transverse myelitis, central nervous system vasculitis and optic neuritis
- Known or suspected drug-induced lupus
- History, clinical evidence, suspicion or significant risk, for thromboembolic events, as well as myocardial infarction, stroke, and/or antiphospholipid syndrome and any participants requiring antithrombotic treatment
- History or current hypogammaglobulinemia
- Serious systemic viral, bacterial or fungal infection
- Participants with a history of invasive opportunistic infections, such as, but not limited to histoplasmosis, listeriosis, coccidioidomycosis, candidiasis, pneumocystis jirovecii, and aspergillosis, regardless of resolution
- Evidence of active or untreated latent tuberculosis as documented by medical history (eg, chest Xrays) and examination, and tuberculosis testing
- High dose of steroids, or a change in dose within 4 weeks prior to randomization
- High dose of antimalarial, or a change in dose within 12 weeks prior to randomization
- High dose of immunosuppressants or a change in dose within 12 weeks prior to randomization
- Use of cyclophosphamide within 3 months prior to screening
- Previous parenteral (IV), intramuscular (IM), or intra-articular steroid administration within 4 weeks prior to randomization
- Participants likely to require multiple courses of oral corticosteroid (OCS) during the study for chronic diseases other than SLE
- Administration of any live (attenuated) vaccine within 3 months prior to randomization (eg, varicella zoster vaccine, oral polio, rabies)
- Administration of any non-live vaccine (eg, seasonal influenza, COVID-19) within 4 weeks prior to randomization
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Frexalimab
Frexalimab intravenous (IV) loading dose followed by subcutaneous (SC) doses, 24 weeks |
Pharmaceutical form: solution Route of administration: Intravenous infusion Pharmaceutical form: solution Route of administration: subcutaneous injection |
|
安慰剂比较:Placebo
Placebo IV loading dose followed by SC, 24 weeks |
Pharmaceutical form: solution Route of administration: Intravenous infusion Pharmaceutical form: solution Route of administration: subcutaneous injection |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of participants who achieved a Systemic Lupus Erythematosus Responder Index (SRI-4) response at Week 24.
大体时间:At Week 24
|
A composite endpoint, with SRI-4 response requiring a ≥ 4-point improvement (reduction) from baseline in Hybrid Safety of Estrogens in Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus Disease Activity Index (hSELENA-SLEDAI), no new British Isles Lupus Assessment Group (BILAG-2004) A organ domain scores, or ≥ 2 new BILAG-2004 B organ domain scores compared with baseline, no worsening from baseline in lupus disease activity, and no permanent discontinuation of study drug or use of new or increased medication for SLE other than defined per protocol. |
At Week 24
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
第 24 周时在预先指定的生物标志物 (BM) 亚组中达到 SRI-4 反应的参与者百分比
大体时间:在第 24 周
|
在第 24 周
|
|
在第 24 周时在预先指定的 BM 亚组中达到基于 BILAG 的综合狼疮评估 (BICLA) 反应的参与者百分比
大体时间:在第 24 周
|
在第 24 周
|
|
在第 24 周获得 BICLA 响应的参与者百分比
大体时间:在第 24 周
|
在第 24 周
|
|
在基线泼尼松≥10 mg/天的亚组中,第 16 周泼尼松剂量≤ 7.5 mg 并维持至第 24 周的参与者百分比
大体时间:直到第 24 周
|
直到第 24 周
|
|
24 周内总累积皮质类固醇剂量
大体时间:直到第 24 周
|
直到第 24 周
|
|
在第 24 周持续减少口服皮质类固醇激素达到 SRI-4 反应的参与者百分比
大体时间:在第 24 周
|
在第 24 周
|
|
在基线 CLASI-A 评分≥8 的参与者亚组中,第 24 周时皮肤红斑狼疮疾病面积和严重程度指数 (CLASI)-A 的百分比相对于基线的百分比变化
大体时间:在第 24 周
|
在第 24 周
|
|
在基线 CLASI-A 评分≥8 的参与者亚组中,第 24 周时 CLASI-A 改善≥50% 的参与者百分比
大体时间:在第 24 周
|
在第 24 周
|
|
在第 24 周时,触痛和肿胀关节数量改善 ≥ 50% 的参与者百分比(在基线时至少有 4 个关节受到影响的参与者中)
大体时间:在第 24 周
|
在第 24 周
|
|
从基线到第 36 周研究结束 (EoS) 的治疗紧急 AE (TEAE)、严重 AE (SAE) 和特殊关注 AE (AESI) 的发生率
大体时间:直到第 36 周
|
直到第 36 周
|
|
从基线到第 36 周 (EoS) 由于 TEAE 导致的研究试验性医药产品永久停药和研究退出的发生率
大体时间:直到第 36 周
|
直到第 36 周
|
|
在生命体征、心电图 (ECG) 和/或实验室评估方面出现显着医学变化的参与者
大体时间:直到第 36 周
|
直到第 36 周
|
|
抗药物抗体 (ADA) 的测量(第 0、4、8、12、16、20、24 周给药前和第 36 周停止治疗后)
大体时间:直到第 36 周
|
直到第 36 周
|
|
SAR441344 随时间的浓度
大体时间:直到第 36 周
|
直到第 36 周
|
|
药代动力学参数:最大浓度(Cmax)
大体时间:直到第 36 周
|
直到第 36 周
|
|
药代动力学参数:达到 Cmax 的时间 (tmax)
大体时间:直到第 36 周
|
直到第 36 周
|
|
药代动力学参数:给药间隔曲线下面积 (AUC0-tau)
大体时间:直到第 36 周
|
直到第 36 周
|
|
药代动力学参数:终末半衰期 (t1/2z)。
大体时间:直到第 36 周
|
直到第 36 周
|
合作者和调查者
赞助
调查人员
- 研究主任:Clinical Sciences & Operations、Sanofi
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- ACT17010
- 2021-001567-25 (EudraCT编号)
- U1111-1266-5011 (注册表标识符:ICTRP)
- 2023-508654-26 (注册表标识符:CTIS)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.